• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期心力衰竭患者的正性肌力治疗。欧洲心脏病学会心力衰竭协会的临床共识声明。

Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology.

作者信息

Gustafsson Finn, Damman Kevin, Nalbantgil Sanem, Van Laake Linda W, Tops Laurens F, Thum Thomas, Adamopoulos Stamatis, Bonios Michael, Coats Andrew Js, Crespo-Leiro Maria G, Mehra Mandeep R, Filippatos Gerasimos, Hill Loreena, Metra Marco, Jankowska Ewa, de Jonge Nicolaas, Kaye David, Masetti Marco, Parissis John, Milicic Davor, Seferovic Petar, Rosano Giuseppe, Ben Gal Tuvia

机构信息

Department of Cardiology, Rigshospitalet, University of Copenhagen, København, Denmark.

University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

Eur J Heart Fail. 2023 Apr;25(4):457-468. doi: 10.1002/ejhf.2814. Epub 2023 Mar 10.

DOI:10.1002/ejhf.2814
PMID:36847113
Abstract

This clinical consensus statement reviews the use of inotropic support in patients with advanced heart failure. The current guidelines only support use of inotropes in the setting of acute decompensated heart failure with evidence of organ malperfusion or shock. However, inotropic support may be reasonable in other patients with advanced heart failure without acute severe decompensation. The clinical evidence supporting use of inotropes in these situations is reviewed. Particularly, patients with persistent congestion, systemic hypoperfusion, or advanced heart failure with need for palliation, and specific situations relevant to implantation of left ventricular assist devices or heart transplantation are discussed. Traditional and novel drugs with inotropic effects are discussed and use of guideline-directed therapy during inotropic support is reviewed. Finally, home inotropic therapy is described, and palliative care and end-of-life aspects are reviewed in relation to management of ongoing inotropic support (including guidance for maintenance and weaning of chronic inotropic therapy support).

摘要

本临床共识声明回顾了晚期心力衰竭患者使用正性肌力支持的情况。当前指南仅支持在急性失代偿性心力衰竭且有器官灌注不良或休克证据的情况下使用正性肌力药物。然而,对于其他无急性严重失代偿的晚期心力衰竭患者,使用正性肌力支持可能是合理的。本文回顾了支持在这些情况下使用正性肌力药物的临床证据。特别讨论了持续充血、全身灌注不足或需要姑息治疗的晚期心力衰竭患者,以及与植入左心室辅助装置或心脏移植相关的特定情况。讨论了具有正性肌力作用的传统和新型药物,并回顾了正性肌力支持期间指南指导治疗的使用情况。最后,描述了家庭正性肌力治疗,并就持续正性肌力支持的管理(包括慢性正性肌力治疗支持的维持和撤机指导)回顾了姑息治疗和临终关怀方面。

相似文献

1
Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology.晚期心力衰竭患者的正性肌力治疗。欧洲心脏病学会心力衰竭协会的临床共识声明。
Eur J Heart Fail. 2023 Apr;25(4):457-468. doi: 10.1002/ejhf.2814. Epub 2023 Mar 10.
2
Outcomes after implantation of partial-support left ventricular assist devices in inotropic-dependent patients: Do we still need full-support assist devices?在依赖血管活性药物的患者中植入部分支持左心室辅助装置后的结果:我们仍然需要全支持辅助装置吗?
J Thorac Cardiovasc Surg. 2014 Sep;148(3):1115-21; discussion 1021-2. doi: 10.1016/j.jtcvs.2014.05.063. Epub 2014 Jun 6.
3
Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.心力衰竭的治疗进展:欧洲心脏病学会心力衰竭协会立场声明。
Eur J Heart Fail. 2018 Nov;20(11):1505-1535. doi: 10.1002/ejhf.1236. Epub 2018 Jul 17.
4
Outpatient parenteral inotropic therapy for advanced heart failure.晚期心力衰竭的门诊胃肠外正性肌力药物治疗
J Heart Lung Transplant. 2000 Aug;19(8 Suppl):S49-57. doi: 10.1016/s1053-2498(99)00107-2.
5
Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).左心室辅助装置作为接受静脉注射正性肌力药物治疗患者的终点治疗选择:来自 REMATCH(慢性心力衰竭机械辅助治疗随机评估)的亚组分析
Circulation. 2004 Aug 24;110(8):975-81. doi: 10.1161/01.CIR.0000139862.48167.23. Epub 2004 Aug 16.
6
Continuous Intravenous Inotropic Support for Advanced Heart Failure: Palliative Considerations.晚期心力衰竭的持续静脉注射正性肌力药物支持:姑息治疗考量
J Pain Palliat Care Pharmacother. 2022 Mar;36(1):59-67. doi: 10.1080/15360288.2022.2050456. Epub 2022 Mar 23.
7
Use of Inotropic Agents in Treatment of Systolic Heart Failure.强心剂在收缩性心力衰竭治疗中的应用。
Int J Mol Sci. 2015 Dec 4;16(12):29060-8. doi: 10.3390/ijms161226147.
8
A review of the contemporary use of inotropes in patients with heart failure.心力衰竭患者中儿茶酚胺类正性肌力药物的当代应用综述
Curr Opin Cardiol. 2024 Mar 1;39(2):104-109. doi: 10.1097/HCO.0000000000001115. Epub 2023 Dec 26.
9
Intravenous continuous home inotropic therapy in advanced heart failure: Insights from an observational retrospective study.静脉连续家庭正性肌力治疗在晚期心力衰竭中的应用:一项观察性回顾性研究的见解。
Eur J Intern Med. 2023 Oct;116:65-71. doi: 10.1016/j.ejim.2023.06.010. Epub 2023 Jun 29.
10
Chronic Intravenous Inotropic Support as Palliative Therapy and Bridge Therapy for Patients With Advanced Heart Failure: A Single-Center Experience.慢性静脉内正性肌力支持作为晚期心力衰竭患者的姑息治疗和桥接治疗:单中心经验。
J Card Fail. 2021 Sep;27(9):974-980. doi: 10.1016/j.cardfail.2021.06.006. Epub 2021 Jun 19.

引用本文的文献

1
Ghrelin peptide in heart failure: when is showtime?心力衰竭中的胃饥饿素肽:何时上演重头戏?
Front Cardiovasc Med. 2025 Jul 4;12:1574521. doi: 10.3389/fcvm.2025.1574521. eCollection 2025.
2
The current use of vasoactive agents in cardiogenic shock related to myocardial infarction and acute decompensated heart failure.血管活性药物在与心肌梗死和急性失代偿性心力衰竭相关的心源性休克中的当前应用。
Am Heart J Plus. 2025 Mar 10;52:100524. doi: 10.1016/j.ahjo.2025.100524. eCollection 2025 Apr.
3
National shortage of home intravenous inotrope agents: The "inotrope pandemic" continues.
国内家庭用静脉注射强心剂短缺:“强心剂大流行”仍在继续。
JHLT Open. 2023 Nov 19;3:100023. doi: 10.1016/j.jhlto.2023.100023. eCollection 2024 Feb.
4
Diuretic strategies in acute decompensated heart failure.急性失代偿性心力衰竭的利尿策略
Heart Fail Rev. 2025 Mar;30(2):417-430. doi: 10.1007/s10741-024-10473-z. Epub 2024 Dec 15.
5
Cardiac tissue engineering: an emerging approach to the treatment of heart failure.心脏组织工程:治疗心力衰竭的一种新兴方法。
Front Bioeng Biotechnol. 2024 Aug 15;12:1441933. doi: 10.3389/fbioe.2024.1441933. eCollection 2024.
6
Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians.心力衰竭的利尿治疗:临床医生实用指南
J Clin Med. 2024 Jul 30;13(15):4470. doi: 10.3390/jcm13154470.
7
Association Between Serial B-Type Natriuretic Peptide Levels, Vasoactive Drug Weaning, and Adverse Cardiovascular Outcomes in Pediatric Heart Failure.在儿科心力衰竭中,连续 B 型利钠肽水平与血管活性药物撤药及不良心血管结局的关系。
J Am Heart Assoc. 2024 Aug 20;13(16):e031132. doi: 10.1161/JAHA.123.031132. Epub 2024 Aug 9.
8
Inotropic Agents: Are We Still in the Middle of Nowhere?正性肌力药物:我们仍在迷茫之中吗?
J Clin Med. 2024 Jun 26;13(13):3735. doi: 10.3390/jcm13133735.
9
2024 update in heart failure.2024年心力衰竭治疗进展
ESC Heart Fail. 2025 Feb;12(1):8-42. doi: 10.1002/ehf2.14857. Epub 2024 May 28.
10
Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry.真实世界心力衰竭人群中接受 Omecamtiv Mecarbil 治疗的资格:来自瑞典心力衰竭注册研究的数据。
PLoS One. 2024 May 24;19(5):e0303348. doi: 10.1371/journal.pone.0303348. eCollection 2024.